doubt it, Scot19 Feb 2013 21:04
consider akt, asm et al
For instance, akt was c20* higher than current sp after a key drug candidate hit the buffers in March 2010, if memory serves:-
"The SAG-O did not consider that the current study provides sufficiently reliable evidence of clinical benefit. The decision to re-intervene following tumour recurrence was made by the individual neurosurgeon on a case by case basis and thus there was no standardised decision making. Therefore, despite the use of a blinded re-intervention committee and the Phase III data showing no evidence of bias on all available re-intervention related study measurements, the SAG-O advised that the data on the primary endpoint could not be considered reliable and therefore did not provide appropriate evidence of a therapeutic benefit for a marketing authorisation. The Company was advised that it must conduct a further study which would need to be powered to show a benefit on an endpoint which was or could be established as clinically and statistically robust.
Following the withdrawal of the Cerepro® MAA, Ark has initiated a full review of its substantial portfolio of assets, their potential and alternative strategies and options to optimise shareholder value. The review will also consider strategic alternatives in light of approaches that have already been received." excerpt from akt "Research Update" March 2010
All opinion only / DYOR / not investment advice in any shape or form (express or implied)
Best of luck with whatever you decide to do...
Sign In
Follow the stocks
